Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

264.69 +0.47 (+0.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 595,003
Open 264.22
Bid (Size) 255.00 (200)
Ask (Size) 267.00 (100)
Prev. Close 264.22
Today's Range 261.59 - 273.00
52wk Range 131.81 - 288.04
Shares Outstanding 139,693,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
From Natera, Inc.
Via Business Wire
News headline image
3 Market-Beating Stocks Worth Your Attention
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca... 
Via StockStory

Performance

YTD
+15.7%
+15.7%
1 Month
+15.7%
+15.7%
3 Month
+27.4%
+27.4%
6 Month
+9.0%
+9.0%
1 Year
+89.2%
+89.2%

More News

Read More
News headline image
Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
From Natera, Inc.
Via Business Wire
News headline image
Billionaire Stanley Druckenmiller's Top Holding Isn't Nvidia. Instead, It's This Under-the-Radar Stock That Wall Street Loves. ↗
Via The Motley Fool
News headline image
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 We Brush Off
Via StockStory
News headline image
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
From Natera, Inc.
Via Business Wire
News headline image
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
From Natera, Inc.
Via Business Wire
News headline image
Why Natera (NTRA) Stock Is Up Today
Via StockStory
Topics Artificial Intelligence
News headline image
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
From Natera, Inc.
Via Business Wire
News headline image
Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
From Natera, Inc.
Via Business Wire
News headline image
1 Healthcare Stock for Long-Term Investors and 2 We Turn Down
Via StockStory
News headline image
1 Cash-Heavy Stock on Our Buy List and 2 We Avoid
Via StockStory
Topics Retirement
News headline image
2 Large-Cap Stocks Worth Your Attention and 1 We Turn Down
Via StockStory
News headline image
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia) ↗
Via The Motley Fool
News headline image
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
From Natera, Inc.
Via Business Wire
News headline image
NWI Management Dumps 42,700 MercadoLibre Shares Worth $82.4 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
From Natera, Inc.
Via Business Wire
News headline image
Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
From Natera, Inc.
Via Business Wire
News headline image
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World
From Natera, Inc.
Via Business Wire

Frequently Asked Questions

Is Natera, Inc. - Common Stock publicly traded?
Yes, Natera, Inc. - Common Stock is publicly traded.
What exchange does Natera, Inc. - Common Stock trade on?
Natera, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Natera, Inc. - Common Stock?
The ticker symbol for Natera, Inc. - Common Stock is NTRA on the Nasdaq Stock Market
What is the current price of Natera, Inc. - Common Stock?
The current price of Natera, Inc. - Common Stock is 264.69
When was Natera, Inc. - Common Stock last traded?
The last trade of Natera, Inc. - Common Stock was at 07/23/26 04:00 PM ET
What is the market capitalization of Natera, Inc. - Common Stock?
The market capitalization of Natera, Inc. - Common Stock is 36.98B
How many shares of Natera, Inc. - Common Stock are outstanding?
Natera, Inc. - Common Stock has 37B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.